Analysts have been eager to weigh in on the Healthcare sector with new ratings on Smith & Nephew Snats (SNN – Research Report), Ocuphire Pharma (OCUP – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report).
Smith & Nephew Snats (SNN)
Canaccord Genuity analyst Caitlin Cronin maintained a Hold rating on Smith & Nephew Snats yesterday and set a price target of $28.00. The company’s shares closed last Monday at $24.54.
According to TipRanks.com, Cronin is a 2-star analyst with an average return of
Smith & Nephew Snats has an analyst consensus of Hold, with a price target consensus of $28.00.
See today’s best-performing stocks on TipRanks >>
Ocuphire Pharma (OCUP)
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Ocuphire Pharma, with a price target of $22.00. The company’s shares closed last Monday at $2.23, close to its 52-week low of $1.85.
According to TipRanks.com, Newman is a 5-star analyst with an average return of
Currently, the analyst consensus on Ocuphire Pharma is a Strong Buy with an average price target of $20.67, which is a 923.3% upside from current levels. In a report issued on March 20, Alliance Global Partners also maintained a Buy rating on the stock with a $20.00 price target.
Vertex Pharmaceuticals (VRTX)
In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Sell rating on Vertex Pharmaceuticals, with a price target of $371.00. The company’s shares closed last Monday at $420.48.
According to TipRanks.com, Ijem is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vertex Pharmaceuticals with a $438.25 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SNN:
- Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
- Smith & Nephew partners with UFC as sports medicine technology provider
- Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
- Smith & Nephew Snats (SNN) Announces Q2 Dividend: Save the Dates!
- Smith & Nephew price target raised to 1,200 GBp from 1,150 GBp at Barclays
